The Long-term Antibody Persistence of MenACWY-TT Vaccine (PF-06866681) Versus Meningitec(Registered) or Mencevax(Registered) ACWY in Healthy Adolescents and Adults and a Booster Dose of MenACWY-TT Administered 10 Years Post Primary Vaccination

NCT01962207 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

243

Enrollment

INDUSTRY

Sponsor class

Conditions

Infections, Meningococcal

Interventions

BIOLOGICAL: Meningococcal vaccine GSK134612

Sponsor

Pfizer